Translational medicine in dermatology: experience in a third-level hospital
DOI:
https://doi.org/10.5281/zenodo.10814393Keywords:
Skin Diseases, Biomarkers, Immunology, Dermatology, Biomedical, Translational ScienceAbstract
Through multidisciplinary research, translational medicine allows a comprehensive approach to diseases in order to provide patients with adequate treatment, whose aim is personalized and precision medicine. In this context, the Cellular Immunology Laboratory of the Immunochemistry Research Unit, and the Dermatology Service of the 21st Century National Medical Center’s Specialties Hospital (Hospital de Especialidades del Centro Médico Nacional Siglo XXI) have achieved a partnership that aspires to provide better quality patient care. This objective is achieved by evaluating the inflammatory skin infiltrates in different pathologies to observe changes in local immunity related to the response to treatment, and with the disease progression distinguish between dermatological diseases, highlight the importance of comprehensive skin care, and make decisions about treatment choice. This article will describe the results obtained from different research protocols (derived from this collaboration) in patients with different dermatoses such as warts, squamous cell carcinoma, mycosis fungoides and psoriasis. The evidence presented highlights the importance of collaborative work between clinical services and research laboratories so that scientific knowledge can be translated towards the comprehensive management of patients and towards personalized and precision medicine.
Downloads
References
Seyhan A. Lost in translation: the valley of death across preclinical and clinical divide-identificatin of problems and overcoming obstacles. Transl Med Commun. 2019;153:547-9. doi: 10.1186/s41231-019-0050-7.
De Maria Marchiano R, Di Sante G, Piro G, et al. Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go. J Pers Med. 2021;11(3):216. doi: 10.3390/jpm11030216.
Kervella D, Le Bas-Bernardet S, Bruneau S, et al. Protection of transplants against antibody-mediated injuries: from xenotransplantation to allogeneic transplantation, mechanisms and therapeutic insights. Front Immunol. 2022;13:932242. doi: 10.3389/fimmu.2022.932242.
Hill GR, Betts BC, Tkachev V, et al. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol. 2021;39:19-49. doi: 10.1146/annurev-immunol-102119-073227.
Lewis T, Kirby E, Kyle JA. Infection in Kidney Transplantation. Contemp Kidney Transplant. 2018;39(8):307.
Voora S, Adey D. Management of kidney transplant recipients by general nephrologists: core curriculum 2019. Am J Kidney Dis. 2019;73(6):866-79 doi: 10.1053/j.ajkd.2019.01.031.
Hartmann J, Schüler S, Enk AH, et al. Skin cancer in organ transplant recipients: dynamics in the incidence and clinical predictors for the first and subsequent post-transplant non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2019;33(7):1281-9. doi: 10.1111/jdv.15538.
Nofal A, Fawzy MM, Eldeeb F, et al. High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts. Dermatol Therapy. 2022;35(12):e15964. doi: 10.1111/dth.15964.
Galindo Noriega I. Determinación de linfocitos CD8 e interferón gamma en paciente trasplantado renal con verrugas antes y a las 6 semanas del tratamiento con isotretinoína [tesis de especialidad]. México: Universidad Nacional Autónoma de México; 2022.
Ramírez Noriega G. Perfil inmunológico de pacientes postrasplantados renales con verrugas, antes y después del tratamiento con isotretinoína [tesis de especialidad]. México: Universidad Nacional Autónoma de México; 2020.
Cheng JY, Li FY, Ko CJ, et al. Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients. JAMA Dermatol. 2018;154(1):60-6. doi: 10.1001/jamadermatol.2017.4506.
Cangemi M, Montico B, Faè DA, et al. Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients. Front Oncol. 2019;9:160. doi: 10.3389/fonc.2019.00160.
Liu J, Geng X, Hou J, et al. New insights into M1/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 2021;21:389. doi: 10.1186/s12935-021-02089-2.
Pan Y, Yu Y, Wang X, et al. Tumor-Associated Macrophages in Tumor Immunity. Front Immunol. 2020;11:583084. doi: 10.3389/fimmu.2020.583084.
Durón Vázquez D. Diferencia en la densidad de macrófagos M2 en carcinoma epidermoide cutáneo de pacientes trasplantados de órgano sólido y no trasplantados [tesis de especialidad]. México: Universidad Nacional Autónoma de México; 2020.
Szlauer-Stefanska A, Kaminska-Winciorek G, Giebel S, et al. Secondary skin neoplasms in patients after autologous and allogeneic hematopoietic stem cell transplantation procedures. Adv Clin Exp Med. 2020;29(10):1221-30. doi: 10.17219/acem/126739.
Prokopenko-Buxbaum N, Pavletic S. Autoimmunity following allogeneic hematopoietic stem cell transplantation. Front Immunol 2020;11:2017. doi: 10.3389/fimmu.2020.02017.
Mawardi H, Hashmi S, Elad S, et al. Chronic graft-versus-host disease: current management paradigm and future perspectives. Oral Dis. 2019;25(4):931-48. doi: 10.1111/odi.12936.
Hernández-Rico B. Identificación de células transformadas mediante el fenotipo asociado al mecanismo de regulación del locus Th2 vía NLRP3 en pacientes con linfoma cutáneo de células T [tesis de maestría]. México: Instituto Politécnico Nacional; 2023.
Huanosta-Murillo E, Alcántara-Hernández M, Hernández-Rico B, et al. NLRP3 Regulates IL-4 Expression in TOX+ CD4+ T Cells of Cutaneous T Cell Lymphoma to Potentially Promote Disease Progression. Front Immunol. 12:668369. doi: 10.3389/fimmu.2021.668369.
Griffiths C, Armstrong A, Gudjonsson J, et al. Psoriasis. Lancet. 2021;397(10281)1301-15. doi: 10.1016/S0140-6736(20)32549-6.
Ortega-Rocha E. Contribución de la pérdida de integridad de la barrera epidermal al microambiente inflamatorio de pacientes con psoriasis [tesis de maestría]. México: Instituto Politécnico Nacional; 2020.
Yokouchi M, Kubo A. Maintenance of tight junction barrier integrity in cell turnover and skin diseases. Exp Dermatol. 2018;27(8):876-83. doi: 10.1111/exd.13742.
Brownstone ND, Hong J, Mosca M, et al. Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics. 2021;15:39-51. doi: 10.2147/BTT.S252578.
Aguilar-Flores C, Castro-Escamilla O, Ortega-Rocha EM, et al. Association of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients. Mediators Inflamm. 2020 Jul 31:2020:8065147. doi: 10.1155/2020/8065147.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Revista Médica del Instituto Mexicano del Seguro Social
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
